Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 18/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31373452 | 1.00 | MAPKAPK2 (0.46) | MAPKAPK2NPSR1L3MBTL1 | |
| SCHEMBL23042885 | 0.85 | NPSR1 (0.41) | MAPKAPK2NPSR1L3MBTL1 | |
| SCHEMBL21256180 | 0.83 | MAPKAPK2 (0.43) | MAPKAPK2 | |
| SCHEMBL13945229 | 0.79 | NPSR1 (0.41) | MAPKAPK2NPSR1L3MBTL1 | |
| SCHEMBL13201540 | 0.77 | NPSR1 (0.42) | MAPKAPK2NPSR1L3MBTL1 | |
| SCHEMBL4019648 | 0.77 | MAPKAPK2 (0.35) | MAPKAPK2 | |
| SCHEMBL23042836 | 0.74 | NPSR1 (0.42) | MAPKAPK2NPSR1L3MBTL1 | |
| SCHEMBL18961127 | 0.72 | NPSR1 (0.49) | MAPKAPK2NPSR1L3MBTL1 | |
| SCHEMBL28048176 | 0.72 | AGBL2 (0.42) | MAPKAPK2 | |
| SCHEMBL31509713 | 0.71 | NPSR1 (0.51) | MAPKAPK2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4524135-A1 | KINESIN KIF18A INHIBITOR AND USE THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023217230-A1 | KINESIN KIF18A INHIBITOR AND USE THEREOF | 上海湃隆生物科技有限公司 | 2023-11-16 | — | — | WO | disclosed |
| US-10179785-B2 | Imidazotriazinone or imidazopyrazinone derivatives, and use thereof | ST PHARM CO., LTD. (KR) | 2019-01-15 | — | — | US | disclosed |
| US-10179785-B2 | Imidazotriazinone or imidazopyrazinone derivatives, and use thereof | ST PHARM CO., LTD. (KR) | 2019-01-15 | — | — | US | disclosed |
| US-20170204101-A1 | COMPOUNDS ANTAGONIZING A3 ADENOSINE RECEPTOR, METHOD FOR PREPARING THEM, AND MEDICAL-USE THEREOF | HANDOK INC. (KR) | 2017-07-20 | — | — | US | disclosed |
| US-20170166572-A1 | NOVEL IMIDAZOTRIAZINONE OR IMIDAZOPYRAZINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2017-06-15 | — | — | US | disclosed |
| US-20170166572-A1 | NOVEL IMIDAZOTRIAZINONE OR IMIDAZOPYRAZINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2017-06-15 | — | — | US | disclosed |
| US-20170166572-A1 | NOVEL IMIDAZOTRIAZINONE OR IMIDAZOPYRAZINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2017-06-15 | — | — | US | disclosed |
| EP-3166946-A2 | NOVEL IMIDAZOTRIAZINONE OR IMIDAZOPYRAZINONE DERIVATIVES, AND USE THEREOF | ST Pharm Co. Ltd. (KR) | 2017-05-17 | — | — | EP | disclosed |
| WO-2016006975-A2 | NOVEL IMIDAZOTRIAZINONE OR IMIDAZOPYRAZINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2016-01-14 | — | — | WO | disclosed |
| WO-2016006975-A2 | NOVEL IMIDAZOTRIAZINONE OR IMIDAZOPYRAZINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2016-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179785-B2 | Imidazotriazinone or imidazopyrazinone derivatives, and use thereof | TNKS1BP1, TPI1, TPMT | MAPKAPK2 905/4885NPSR1 4330/4885L3MBTL1 4048/4885 |
| US-20170204101-A1 | COMPOUNDS ANTAGONIZING A3 ADENOSINE RECEPTOR, METHOD FOR PREPARING THEM, AND MEDICAL-USE THEREOF | ADORA2A, ADORA3, ADORA1 | MAPKAPK2 3271/4885NPSR1 404/4885L3MBTL1 4829/4885 |
| US-20170166572-A1 | NOVEL IMIDAZOTRIAZINONE OR IMIDAZOPYRAZINONE DERIVATIVES, AND USE THEREOF | TNKS1BP1, TPI1, TBKBP1 | MAPKAPK2 812/4885NPSR1 4318/4885L3MBTL1 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.